| Intravenous versus oral acetaminophen for pain: systematic review of current evidence to support clinical decision-making F Jibril, S Sharaby, A Mohamed, KJ Wilby The Canadian journal of hospital pharmacy 68 (3), 238, 2015 | 184 | 2015 |
| Identification of HLA-DRB1 association to adalimumab immunogenicity M Liu, J Degner, JW Davis, KB Idler, A Nader, NM Mostafa, JF Waring PLoS One 13 (4), e0195325, 2018 | 70 | 2018 |
| Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis M Shebley, AR Polepally, A Nader, JW Ng, I Winzenborg, CE Klein, ... Clinical pharmacokinetics 59 (3), 297-309, 2020 | 49 | 2020 |
| Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration RF Eyler, AM Vilay, AM Nader, M Heung, M Pleva, KM Sowinski, ... Antimicrobial agents and chemotherapy 58 (3), 1320-1326, 2014 | 46 | 2014 |
| Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis NM Mostafa, AM Nader, P Noertersheuser, M Okun, WM Awni Journal of the European Academy of Dermatology and Venereology 31 (3), 490-497, 2017 | 39 | 2017 |
| Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa A Nader, D Beck, P Noertersheuser, D Williams, N Mostafa Clinical Pharmacokinetics 56, 1091-1102, 2017 | 34 | 2017 |
| Suitability of digoxin as a P‐glycoprotein probe: implications of other transporters on sensitivity and specificity AM Nader, DR Foster The Journal of Clinical Pharmacology 54 (1), 3-13, 2014 | 34 | 2014 |
| Clinical and pharmacokinetic outcomes of peak–trough-based versus trough-based vancomycin therapeutic drug monitoring approaches: A pragmatic randomized controlled trial FK Al-Sulaiti, AM Nader, MO Saad, A Shaukat, R Parakadavathu, ... European Journal of Drug Metabolism and Pharmacokinetics 44, 639-652, 2019 | 33 | 2019 |
| Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, or atopic dermatitis: population analyses of … A Nader, S Stodtmann, A Friedel, MEF Mohamed, AA Othman The Journal of Clinical Pharmacology 60 (4), 528-539, 2020 | 32 | 2020 |
| Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters A Nader, N Zahran, A Alshammaa, H Altaweel, N Kassem, KJ Wilby European journal of drug metabolism and pharmacokinetics 42, 221-228, 2017 | 32 | 2017 |
| Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine AM Nader, SK Quinney, HM Fadda, DR Foster The AAPS Journal, 1-8, 2016 | 30 | 2016 |
| Population pharmacokinetics of elagolix in healthy women and women with endometriosis I Winzenborg, A Nader, AR Polepally, M Liu, J Degner, CE Klein, ... Clinical pharmacokinetics 57, 1295-1306, 2018 | 27 | 2018 |
| A semi‐mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics SK Quinney, AN Mohamed, MF Hebert, DM Haas, S Clark, JG Umans, ... CPT: pharmacometrics & systems pharmacology 1 (9), 1-9, 2012 | 24 | 2012 |
| Exposure–response analyses of upadacitinib efficacy and safety in phase II and III studies to support benefit–risk assessment in rheumatoid arthritis A Nader, MEF Mohamed, I Winzenborg, E Doelger, P Noertersheuser, ... Clinical Pharmacology & Therapeutics 107 (4), 994-1003, 2020 | 22 | 2020 |
| A genetic variant in the BCL2 gene associates with adalimumab response in hidradenitis suppurativa clinical trials and regulates expression of BCL2 M Liu, J Degner, RW Georgantas, A Nader, NM Mostafa, HD Teixeira, ... Journal of investigative dermatology 140 (3), 574-582. e2, 2020 | 20 | 2020 |
| Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis BS Decker, AN Mohamed, M Chambers, MA Kraus, SM Moe, ... American journal of nephrology 36 (2), 144-150, 2012 | 16 | 2012 |
| Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis R Gniadecki, CL Leonardi, KB Gordon, Y Gu, Z Geng, A Nader, ... Journal of the European Academy of Dermatology and Venereology 32 (8), 1297-1304, 2018 | 13 | 2018 |
| Exposure‐safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis‐associated pain A Abbas Suleiman, A Nader, I Winzenborg, D Beck, AR Polepally, J Ng, ... CPT: Pharmacometrics & Systems Pharmacology 9 (11), 639-648, 2020 | 11 | 2020 |
| Drug–drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy A Nader, NM Mostafa, F Ali, M Shebley Clinical pharmacokinetics 60, 133-143, 2021 | 10 | 2021 |
| Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to … R Fleischmann, A Friedman, E Drescher, A Singhal, G Cortes-Maisonet, ... The Lancet Rheumatology 4 (6), e395-e406, 2022 | 6 | 2022 |
